Multiple inflammatory pathway targets

Multiple inflammatory pathway targets refers to a broad therapeutic strategy or a group of molecular entities that collectively mediate the inflammatory response, rather than a single specific receptor or enzyme. This concept involves the simultaneous modulation of several key signaling cascades, such as the Nuclear Factor-kappa B (NF-kappaB), Mitogen-Activated Protein Kinase (MAPK), and Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathways (Liu et al., 2017, https://www.nature.com/articles/sigtrans201723). Drugs that address multiple targets, most notably glucocorticoids like dexamethasone, act by binding to the glucocorticoid receptor to transrepress numerous pro-inflammatory genes and interfere with multiple signaling nodes (Ramamoorthy & Cidlowski, 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712657/). This multi-target approach is essential for managing complex, multi-factorial diseases like rheumatoid arthritis, systemic lupus erythematosus, and severe asthma, where inhibiting a single cytokine may be insufficient. However, the broad suppression of these pathways often leads to significant safety challenges, including increased susceptibility to infections and various systemic metabolic side effects (Pang et al., 2012, https://www.nature.com/articles/nrd3722). Modern drug discovery also explores polypharmacology through multi-kinase inhibitors or bifunctional antibodies to achieve synergistic anti-inflammatory effects with improved safety profiles.

Other names

Multi-target anti-inflammatory approachInflammatory signaling networkPolypharmacological inflammatory targets

Broad-spectrum inhibition of multiple signaling nodes (e.g., NF-kappaB, MAPK, JAK-STAT) and enzymatic pathways (e.g., COX/LOX) to suppress the inflammatory cascade.